Exclusive Summary

• - Core patents have expired and the drug is not approved in US/EU, enabling low-IP-risk entry and potential first-to-market positions in many regions.
• - Addresses very large pain/arthritis populations (OA ~528M; low back pain ~619M) with stable and growing demand.
• - As an NSAID, it is guideline-endorsed first-line therapy; clinical data show non-inferiority to celecoxib, supporting competitive positioning.
• - KR-MFDS GMP originator with Korean registration provides strong compliance and a ready dossier for accelerated approvals.
• - Mature manufacturing and low COGS support competitive pricing, with clear advantage versus COX-2 originators for tender and distribution.

Asset Materials

Contact Us for Full Materials